The demo realized equally its Most important endpoints, with semaglutide two.four mg demonstrating statistically substantial and remarkable improvements in liver fibrosis without having worsening of steatohepatitis, as well as resolution of steatohepatitis without having worsening of liver fibrosis in individuals with MASH in comparison to placebo.